SM Musculoskeletal Disorders最新文献

{"title":"Impact of Biofield Energy Healing Treatment: Evaluation of AntiRheumatoid Activity Using Synovial Sarcoma Cell Line (SW982)","authors":"M. Trivedi, S. Jana","doi":"10.36876/smmd.1034","DOIUrl":"https://doi.org/10.36876/smmd.1034","url":null,"abstract":"The present research was performed to monitor the anti-rheumatoid action of Consciousness Energy Healing based DMEM medium using synovial sarcoma cell line, SW982. The study included the evaluation of bone health potential using inflammatory parameter, IL-8. The test item (DMEM medium) was divided into three parts, first part received a one-time Consciousness Energy Healing Treatment by a renowned Biofield Energy Healer, Mahendra Kumar Trivedi and was labeled as the one-time Biofield Energy Treated (BT-I) DMEM, while second part received the two-times the Biofield Energy Treatment and is denoted as BT-II DMEM. The third part did not receive any treatment and defined as the untreated DMEM group. Cell viability assay using MTT method showed that the cell viability of SW982 cells was 113.8% and 88.3% in the BT-I and BT-II groups, respectively. The BT-I group demonstrated significant (p≤0.001) inhibition of IL-8 by 27.74%, while BT-II group also showed a significant (p≤0.001) inhibition of IL-8 by 45.66% as compared to the untreated DMEM group. In conclusion, the data suggested that the Consciousness Energy Healing Treatment significantly inhibited the pro-inflammatory cytokine (IL-8) that showed anti-rheumatic action and can also be used in other bone and inflammatory disorders such as osteoporosis, Paget’s disease of bone, rickets, deformed bones, osteomalacia, osteoma, stress, aging, bone loss, and fractures along with autoimmune disorders and overall quality of life.","PeriodicalId":132433,"journal":{"name":"SM Musculoskeletal Disorders","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127057900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Exostosis Disease: Study of Three Senegalese Families","authors":"N. Moustapha, Kane Baïdy Sy, Salissou Garba Mahaman, Sarr Lamine, D. Coumba, Akpo L. Geraud, D. A. Badara, Diallo Saidou, Ndongo Souhaibou, Pouye Abdoulaye","doi":"10.36876/smmd.1032","DOIUrl":"https://doi.org/10.36876/smmd.1032","url":null,"abstract":"Exostosis is a benign tumour corresponding to a well-differentiated bone excrescence, produced by a germinal cartilage cap during growth [1,2]. It is most often sporadic, but it can also be part of an autosomal dominant, multiple exostosis disease known as Bessel-Hagen disease [1]. Exostosis, especially in its solitary form, represents the most frequent benign tumour (20 to 50% of benign bone tumours and 10 to 15% of all bone tumours) [1]. The multiple exostosis disease is a rare disease first described by Boyer in 1814 [3-5]. It is mainly reported in Western literature where its prevalence is estimated at 1/50,000 [3,5] and, to a lesser extent, in North Africa [6,7]. This prevalence has not been determined in the African population. However, work has been carried out on the disease in North Africa and sub-Saharan Africa [3-12]. Studies evaluating family forms of the disease were mainly carried out in the Western literature [12-18]. In sub-Saharan Africa, reported cases are apparently sporadic. The objective of this work was to study the epidemiological, diagnostic and therapeutic aspects of familial forms of multiple exostosis disease.","PeriodicalId":132433,"journal":{"name":"SM Musculoskeletal Disorders","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126815060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ledderhose’s Disease-What do We Know and What do We not know","authors":"I. Schmidt","doi":"10.36876/smmd.1033","DOIUrl":"https://doi.org/10.36876/smmd.1033","url":null,"abstract":"Plantar fibromatosis of the foot is a rare benign, hyperproliferative, and local aggressive disease of the plantar aponeurosis (i.e. fascia) (Figure 1A) of unknown etiology and included among the extra-abdominal desmoids tumors, this entity was first described in 1894 bythe German physician Georg Ledderhose (1855-1925), and it is accompanied by a high recurrence rate [1-3]. Regarding etiology, it has been described to be most frequent in patients with diabetes, low body weight, epilepsy, alcohol abuse, and smoking, and a familial history in up to 19.1% of cases is observed as well [2,4]. Occurrence is observed at all ages ranging from 2 to 83 years (N=178), but especially in the 4th and 5th decade of life in the absence of significant sex-related differences (51.7% male vs. 48.3% female in 178 patients), and bilateral involvement is reported to be 20-50% of cases [2,4]. It can be associated in 5-21.3% of cases with the palmar fibromatosis of the hand (Figure 2A-D) first described quite earlier in 1831by the French physician Baron Guillaume Dupuytren (17771835) which can also be associated with the fibrous subcutaneous nodules (i.e. knuckle pads) upon the proximal interphalangeal finger joints (Figure 3) first described in1904 by the British physician SirArchibald Edward Garrod (1857-1936), and in 1-3% of cases with the penile fibromatosis first described substantial quite earlier in 1743 by the French physician François Gigot de la Peyronie (1678-1747) [2,5-12]. Histopathological findings in plantar fibromatosis reveal similar findings to those in palmar fibromatosis [13]. In the literature, it has been proposed for palmar fibromatosis that growth factors, such as platelet-derived growth factor and transforming growth factor-beta, free oxidized radicals, increased levels of plasminogen activator enzymes, and expression of Ki-67 antigen contribute the etiology, and it was found that the number of androgen receptors in specimens of palmar fibromatoses was considerably higher than in normal palmar fascia [14-19]. Noted that expression of the Ki-67 antigen plays an important role in detection of malignancies [20]. For the palmar fibromatosis, family history probably has the strongest influence on the age at time of first surgery compared to environmental factors, followed by male sex, and the percentage of familial cases decreased with age of onset from 55% in patients aged 40-49 years to 17% in patientsaged80 years and older, and men are upto 15 times more likely to suffer from this disease but during the 8th and 9th decade of life the ratio between affected men and women is equal [21,22]. Moreover, palmar fibromatosis is more frequently observed in the white Caucasian and Nordic race than in Africa or Asia [23]. Noted that the incidence of palmar fibromatosis in elderly men is reported to be up to 25.3% in Australia [24], up to 28.9% in Ireland [25], and up to 13.75% in England [26]. The differential diagnosis of plantar fibromatosis should include","PeriodicalId":132433,"journal":{"name":"SM Musculoskeletal Disorders","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117134463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}